Characterization of Plasmodium liver stage inhibition by halofuginone.

ABSTRACT: Malaria is a devastating parasitic disease that afflicts one-third of the world's population. Antimalarial drugs in common use address few targets, and their efficacy is being undermined by parasite resistance. Most therapeutics target blood-stage malaria, whereas only few compounds are active against malaria's liver stage, the first stage of the Plasmodium parasite's life cycle within the human host. The identification of inhibitors active against liver-stage malaria would benefit the development of chemical probes to elucidate the poorly understood biology of this phase of the parasite life cycle and could provide agents to prevent and eliminate the disease. Herein we report the development of a live-cell parasite traversal assay in 384-well format amenable to high-throughput screening t

SUBMITTER: Derbyshire ER 

PROVIDER: S-EPMC3359061 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature